Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a quantitative cell-based relative potency assay for LUXTURNA.

Molecular therapy. Methods & clinical development·2025
Same author

High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.

The AAPS journal·2023
Same author

Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.

The AAPS journal·2021
Same author

3,3'-Diindolylmethane enhances apoptosis in docetaxel-treated breast cancer cells by generation of reactive oxygen species.

Pharmaceutical biology·2018
Same author

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.

ERJ open research·2016

Related Experiment Video

Updated: Jun 17, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

CCL2 blockade augments cancer immunotherapy.

Zvi G Fridlender1, George Buchlis, Veena Kapoor

  • 1Thoracic Oncology Research Laboratory and Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6160, USA. gfrid@mail.med.upenn.edu

Cancer Research
|December 24, 2009
PubMed
Summary
This summary is machine-generated.

Blocking CCL2 (monocyte chemoattractant protein-2) with antibodies enhances cancer vaccine effectiveness. This approach reduces tumor immunosuppression and boosts T-cell responses, leading to significant tumor reduction and cures in preclinical models.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 17, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Tumor microenvironments often suppress immune responses, hindering cancer vaccine efficacy.
  • Monocyte chemoattractant proteins, like CCL2, contribute to this immunosuppression through direct and indirect mechanisms.

Purpose of the Study:

  • To investigate if blocking CCL2 can reduce tumor immunosuppression and enhance vaccine immunotherapy.
  • To evaluate the impact of combining CCL2 blockade with cancer vaccines in preclinical models.

Main Methods:

  • Administration of anti-murine CCL2/CCL12 monoclonal antibodies alongside cancer vaccines in three distinct tumor models (NSCLC, mesothelioma).
  • Assessment of tumor growth, intratumoral cytotoxic T cells (CD8+), immunosuppressive cells (T regulatory cells), and the tumor microenvironment.

Main Results:

  • Combination therapy significantly augmented vaccine efficacy, leading to reduced tumor volume and cures in approximately 50% of cases.
  • Enhanced intratumoral CD8+ T cells, increased activation, and improved antigen specificity were observed.
  • A notable reduction in intratumoral T regulatory cells was a key mechanism of action.

Conclusions:

  • CCL2 is a critical cytokine mediating tumor-induced immunosuppression.
  • CCL2 blockade, in combination with cancer vaccines, offers a promising strategy to enhance antitumor CD8+ T-cell responses.
  • This combination warrants consideration for future cancer immunotherapy clinical trials.